Everest Medicines Limited
Research Everest Medicines Limited (1952.HK) on Bullrun: market cap HKD 11.44B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker1952.HK
- ExchangeHK
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyHKD
- Market capHKD 11.44B
- Financial periodFY2025
- RevenueCNY 1.71B
- Revenue growth141.5%
- Net income-CNY 297.77M
- Free cash flow-CNY 440.90M
- Gross margin69.3%
Valuation Snapshot
latest market cap is HKD 11.44B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 1.71B | -CNY 297.77M | -CNY 440.90M | 69.3% | -0.89 | CNY 1.84B | CNY 926.28M | CNY 5.30B |
| FY2024 | CNY 706.68M | -CNY 1.04B | -CNY 883.66M | 74.6% | -3.24 | CNY 884.47M | CNY 549.24M | CNY 4.07B |
| FY2023 | CNY 125.93M | -CNY 844.46M | -CNY 1.04B | 72.7% | -2.7 | CNY 523.06M | CNY 510.63M | CNY 4.97B |
| FY2022 | CNY 12.79M | -CNY 247.28M | -CNY 1.59B | 63.7% | -0.83 | CNY 490.79M | CNY 79.63M | CNY 5.65B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | HKD 11.44B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 HKD.
About Everest Medicines Limited
Everest Medicines Limited, a biopharmaceutical company, engages in the discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets. It pipeline includes Nefecon, an oral formulation of budesonide for the treatment of immunoglobulin nephropathy (IgAN);
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Everest Medicines Limited's market cap?
Everest Medicines Limited's market capitalization is HKD 11.44B.
What does Everest Medicines Limited do?
Everest Medicines Limited, a biopharmaceutical company, engages in the discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets.